Literature DB >> 23412534

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

Neeraj Pandey, Vandana Dwivedi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412534      PMCID: PMC3638339          DOI: 10.4103/0301-4738.107211

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Dear Editor, We read the article by Shah et al.[1] with great interest. At first, we would like to congratulate the authors for a very nice case reported here. We have a few comments to make on this case report. Inflammatory choroidal neovascular membrane (CNVM) is not so uncommon to be seen as reported in the case and it may be associated with toxoplasmosis, tuberculosis, etc.[23] Subretinal fluid (SRF) mentioned in Fig. 1 (color picture) is not very well supported by Fig. 2 where optical coherence tomography (OCT) does not show any SRF. Instead, it does show scarring. Blocked fluorescence seen in Fig. 2 may be due to the pigmentation around the lesion which may be a sign of longstanding lesion with retinal pigment epithelium (RPE) alteration. Hyperfluorescence seen in Fig. 2 may be staining of scar as it is a late phase angiogram picture. No early phase picture is shown in the support of early leak of CNVM. Fig. 3 is shown in the article as no leak with regressed CNVM, which is an early phase picture and it may take stain in late phase as in Fig. 2 if it was only scar. It is well supported by the OCT showing shadowing of the reflectivity behind the scar. Both the OCTs shown in Figs. 2 and 3 are probably not passing through the same place, so we cannot compare the reflectivity and shadowing of these two pictures.
  3 in total

1.  Macular subretinal neovascularization in choroidal tuberculosis.

Authors:  Y M Chung; T S Yeh; S J Sheu; J H Liu
Journal:  Ann Ophthalmol       Date:  1989-06

2.  Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis.

Authors:  Alfredo Adán; Carlos Mateo; Charlotte Wolley-Dod
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

3.  Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

Authors:  Nikunj J Shah; Urmi N Shah
Journal:  Indian J Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 1.848

  3 in total
  2 in total

1.  Results of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization.

Authors:  Sourour Zina; Sana Khochtali; Alessandro Invernizzi; Imen Ksiaa; Ben Amor Hager; Francesco Viola; Nesrine Abroug; Moncef Khairallah
Journal:  J Curr Ophthalmol       Date:  2021-03-26

Review 2.  Changing paradigms of anti-VEGF in the Indian scenario.

Authors:  P Mahesh Shanmugam
Journal:  Indian J Ophthalmol       Date:  2014-01       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.